Biovail Seeks to Assure Investors Spooked by FDA Letter

Biovail Corp. sought Monday to allay investor concerns over its announcement last week that its application for a new version of its antidepressant Wellbutrin XL had been rejected by the U.S. Food and Drug Administration.
Canada.com